Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/8868
Full metadata record
DC FieldValueLanguage
dc.contributor.authorWicaksono Pitoyo, Ceva-
dc.contributor.authorMartin Rumende, Cleopas-
dc.contributor.authorK. Wiraputri, Anindita-
dc.contributor.authorRatri Audita, Fatira-
dc.date.accessioned2024-12-13T02:06:40Z-
dc.date.available2024-12-13T02:06:40Z-
dc.date.issued2022-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/8868-
dc.description.abstractAlectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The most common adverse effects of alectinib are fatigue, constipation, edema, myalgia and anemia. Meanwhile, bradycardia was reported as a very common adverse effect, but generally asymptomatic, unlike the reported patient in this case report. This case report’s purpose is to increase awareness of the possibility of adverse effects due to alectinib administration that require immediate intervention in order to improve the quality of life and patient survival, especially in patients with advanced NSCLC. Keywords: alectinib, bradycardia, NSCLCen_US
dc.subjectalectinib, bradycardia, NSCLCen_US
dc.titleSymptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLCen_US
dc.typeArticleen_US
Appears in Collections:VOL 54 NO 2 2022

Files in This Item:
File Description SizeFormat 
15.pdf553.54 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.